Table 3.
Systemic adverse events (%) related to co-administration of HBRV and MenCC or their sequential administration28.
| Group 1 (Co-administration) |
Group 2 (Sequential administration) |
|||||
|---|---|---|---|---|---|---|
| Systemic AEs (%) | Post-dose 1* | Post-dose 2* | Post-dose 3** | Post-dose 1** | Post-dose 2** | Post-dose 3** |
| Any (solicited/unsolicited) related to HBRV | 65.5 | 42.6 | <10 | NR | <10 | <10 |
| Any solicited related to HBRV | 44.0 | 27.0 | NR | NR | NR | NR |
| Diarrhea | 23.3^ | 13.0^ | 6.4 | 13.1 | 8.3 | 5.9 |
| Vomiting | 19.8^ | 10.4^ | NR | 5.7 | NR | NR |
| Fever | 8.6^ | 18.3^ | NR | NR | NR | NR |
| Any unsolicited related to HBRV | 45.7 | 24.3 | NR | NR | NR | NR |
*After co-administration of HBRV and MenCC vaccines. ** After sequential administration.
^ Unclear if related to meningococcal vaccine or HBRV vaccine. AE: Adverse event. NR: Not reported. HBRV: human-bovine live-attenuated reassortant pentavalent rotavirus vaccine. MenCC: MenC tetanus toxoid conjugate vaccine.